Esperion Therapeutics (ESPR) Short-term Investments (2013 - 2023)

Esperion Therapeutics has reported Short-term Investments for 11 years, with the latest figure at $17.4 million in Q1 2023.

• For the quarter ending Q1 2023, Short-term Investments fell 74.42% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2023 stood at $17.4 million (down 74.42% YoY), and the FY2022 full-year result was $42.1 million, down 16.56% from the prior year.
• Short-term Investments for Q1 2023 stood at $17.4 million, down from $42.1 million in the prior quarter.
• The five-year high for Short-term Investments was $68.1 million in Q1 2022, with the low at $2.2 million in Q2 2020.
• Historically, Short-term Investments has averaged $35.7 million across 5 years, with a median of $33.3 million in 2019.
• Annual changes were most pronounced in 2020 — Short-term Investments tumbled 91.64% — and 2022, when it slipped 16.56%.
• Esperion Therapeutics' Short-term Investments stood at $34.7 million in 2019, then slumped by 93.52% to $2.2 million in 2020, then surged by 2144.82% to $50.4 million in 2021, then slipped by 16.56% to $42.1 million in 2022, then sank by 58.59% to $17.4 million in 2023.
• The last three Short-term Investments figures came in at $17.4 million (Q1 2023), $42.1 million (Q4 2022), and $29.9 million (Q3 2022), per Business Quant data.